CAL
PCRX icon

Capital Advisors Ltd’s Pacira BioSciences PCRX Stock Holding History

Capital Advisors Ltd’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
+2
New +$47 ﹤0.01% 1531
2024
Q3 		– Sell
-10
Closed – – 1551
2024
Q2 		$0 Buy
+10
New +$285 ﹤0.01% 1580
2023
Q4 		– Sell
-8
Closed – – 1437
2023
Q3 		$0 Buy
+8
New +$288 ﹤0.01% 1429

Other funds holding PCRX

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
MAM
Milestone Asset Management Pittsburgh, Pennsylvania $636M AUM 22.1% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Capital Advisors Ltd's PCRX Position: Q2 2026 in Review

Capital Advisors Ltd opened a new position in Pacira BioSciences (PCRX) in Q2 2026: 2 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #1531 among its holdings. This is a return to the name: Capital Advisors Ltd previously reported a position in PCRX as recently as Q2 2024.

Capital Advisors Ltd first reported a position in PCRX in Q3 2023 and has held it in 3 quarters since. 26 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Capital Advisors Ltd held 2 shares of Pacira BioSciences worth $0 as of Q2 2026.
  • Pacira BioSciences was a new Capital Advisors Ltd position in Q2 2026.
  • Pacira BioSciences made up ﹤0.01% of Capital Advisors Ltd's portfolio in Q2 2026, its #1531 holding.
  • Capital Advisors Ltd first reported a position in Pacira BioSciences in Q3 2023 and has held it in 3 quarters since.
  • 26 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Capital Advisors Ltd's 13F filing for Q2 2026, filed 16 Jul 2026.